GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Concord Healthcare Group Co 2453.HK · HKD

N/A · HKEX · 🇭🇰 Hong Kong

Compare

0.62

+0.81%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2024

Revenue

CN¥388.3m

FY2014FY2024

Net income

−CN¥443.2m

FY2014FY2024

Free cash flow

−CN¥511.4m

FY2014FY2024

Shareholders' equity

CN¥1.65bn

FY2014FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2014
RevenueCN¥388.3mCN¥538.6mCN¥472.2mCN¥470.5mCN¥166.3mCN¥63.0m
Research and developmentCN¥31.2mCN¥36.4mCN¥41.3mCN¥40.4mCN¥11.3m—
Operating income−CN¥393.4m−CN¥332.0m−CN¥378.1m−CN¥440.0m−CN¥283.9mCN¥9.4m
Net income−CN¥443.2m−CN¥373.1m−CN¥541.4m−CN¥816.6m−CN¥583.3mCN¥6.2m
Diluted earnings per share-0.62-0.52-0.76-1.14-0.810.18

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2014
Total assetsCN¥5.91bnCN¥5.24bnCN¥5.41bnCN¥5.45bnCN¥4.98bnCN¥140.2m
Cash and short-term investmentsCN¥337.1mCN¥40.6mCN¥126.5mCN¥136.1mCN¥424.8mCN¥79.6m
Total liabilitiesCN¥4.26bnCN¥3.64bnCN¥3.73bnCN¥7.00bnCN¥5.66bnCN¥75.3m
DebtCN¥3.21bnCN¥2.60bnCN¥2.61bnCN¥2.44bnCN¥2.17bn—
Shareholders' equityCN¥1.65bnCN¥1.60bnCN¥1.69bn−CN¥1.56bn−CN¥678.1mCN¥64.9m
Shares outstanding715m716m716m716m716m34m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2014
Cash from operations−CN¥186.0mCN¥509.2m−CN¥93.6mCN¥151.2mCN¥50.6mCN¥11.9m
Capital spending−CN¥325.4m−CN¥183.7m−CN¥84.9m−CN¥522.8m−CN¥768.5m−CN¥1.6m
Free cash flow−CN¥511.4mCN¥325.5m−CN¥178.5m−CN¥371.6m−CN¥717.9mCN¥10.3m

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022Jun 2015
RevenueCN¥200.9mCN¥169.3mCN¥219.0mCN¥253.5mCN¥285.2mCN¥328.4mCN¥143.8mCN¥30.8m
Operating income−CN¥135.5m−CN¥240.1m−CN¥153.2m−CN¥163.1m−CN¥166.3m−CN¥178.9m−CN¥199.2mCN¥864,000
Net income−CN¥176.6m−CN¥261.3m−CN¥181.9m−CN¥178.8m−CN¥194.3m−CN¥160.2m−CN¥381.2mCN¥3.4m
Diluted earnings per share-0.24-0.37-0.25-0.25-0.27-0.22-0.530.10
Total assets—CN¥5.91bnCN¥5.72bnCN¥5.24bnCN¥5.51bn——CN¥111.9m
Cash and short-term investments—CN¥337.1mCN¥318.7mCN¥40.6mCN¥257.3m——CN¥59.5m
Debt—CN¥3.02bnCN¥2.43bnCN¥2.23bnCN¥2.39bn———
Shareholders' equity—CN¥1.65bnCN¥1.91bnCN¥1.60bnCN¥1.79bn——CN¥52.9m

Financial ratios

Data as of 4 Nov 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Operating margin-47.6%-79.5%-60.3%-99.5%-93.5%-171.9%
Net margin-55.8%-114.1%-69.3%-114.7%-173.6%-350.7%
Return on equity-13.7%-26.9%-23.3%-32.1%52.4%86.0%
Return on assets-4.3%-7.5%-7.1%-8.9%-12.3%-9.9%
Free cash flow yield7.2%26.7%91.2%-2.9%184.9%—
Revenue growth15.4%-27.9%14.1%0.4%182.9%31.5%
Earnings growth-43.6%18.8%-31.1%-33.7%40.0%107.9%
Current ratio0.54x0.63x0.30x0.84x0.20x0.21x
Debt to equity1.64x1.89x1.54x1.58x-1.47x-0.23x
Equity ratio31.6%27.9%30.5%27.7%-23.4%-11.5%
Interest coverage-1.77x-2.82x-3.01x-1.71x-1.01x-0.88x
R&D as a share of sales6.1%8.0%6.8%8.8%8.6%6.8%
Buybacks as a share of market value2.2%-13.4%-5.8%5.5%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-6.2%43.9%—
Operating income-3.7%——
Net income-18.4%——

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-78.3%-82.6%-86.6%—
Net margin-88.1%-116.3%-131.1%—

Valuation history

At each fiscal year end

FY2024
Price to earnings-15.4
Price to sales17.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.